These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3859212)

  • 61. Imipenem/cilastatin treatment of multiresistant Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Pedersen SS; Pressler T; Høiby N; Bentzon MW; Koch C
    J Antimicrob Chemother; 1985 Nov; 16(5):629-35. PubMed ID: 3935639
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [A clinical evaluation of MK-0787/MK-0791 for long-term administration in urological infections].
    Suzuki K; Takanashi K; Naide Y; Fujita T; Ogawa T; Hirabayashi S; Tamai H; Yanaoka M; Ishiguro K; Asano H
    Hinyokika Kiyo; 1986 Sep; 32(9):1387-408. PubMed ID: 3101448
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of cefotaxime, imipenem-cilastatin, ampicillin-gentamicin, and ampicillin-chloramphenicol in the treatment of experimental Escherichia coli bacteremia and meningitis.
    Kim KS
    Antimicrob Agents Chemother; 1985 Sep; 28(3):433-6. PubMed ID: 3907493
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetics.
    Calandra GB; Raupp W; Brown KR
    Scand J Infect Dis Suppl; 1987; 52():15-9. PubMed ID: 3483286
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety and efficacy of imipenem/cilastatin in treatment of complicated urinary tract infections.
    Cox CE; Corrado ML
    Am J Med; 1985 Jun; 78(6A):92-4. PubMed ID: 3859220
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Clinical evaluation of imipenem/cilastatin sodium in children].
    Meguro H; Arimasu O; Kobayashi M; Shiraishi H; Fujii R; Izumi K
    Jpn J Antibiot; 1986 Jul; 39(7):1715-32. PubMed ID: 3464775
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Imipenem/cilastatin sodium in the treatment of obstetric and gynecologic infections].
    Doko F
    Jpn J Antibiot; 1986 May; 39(5):1427-31. PubMed ID: 3463788
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy of imipenem/cilastatin in patients with severe bacterial infections.
    Reutter FW
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():141-4. PubMed ID: 3469186
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tentative interpretive criteria for in vitro antibacterial susceptibility testing with imipenem.
    Shungu DL; Cerami AT; Weinberg E; Capizzi T; Gadebusch HH
    J Clin Microbiol; 1986 Mar; 23(3):421-4. PubMed ID: 3514655
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field].
    Nishimura T; Tabuki K; Takashima T; Takagi M
    Jpn J Antibiot; 1986 Jul; 39(7):1867-78. PubMed ID: 3464783
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Imipenem: a new carbapenem antibiotic.
    Lipman B; Neu HC
    Med Clin North Am; 1988 May; 72(3):567-79. PubMed ID: 3280907
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Imipenem: first of a new class of beta-lactam antibiotics.
    Barza M
    Ann Intern Med; 1985 Oct; 103(4):552-60. PubMed ID: 3898954
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Fundamental and clinical studies on imipenem/cilastatin sodium in the field of pediatrics].
    Nakashima T; Nakashima S; Hayakawa F; Miyachi Y; Hakamada S; Kuno K
    Jpn J Antibiot; 1986 Jul; 39(7):1828-46. PubMed ID: 3464781
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Hemostatic parameters influenced by imipenem/cilastatin].
    Ziemen M; Shah PM; Henkel-Bussmann M; Breddin HK
    Infection; 1986; 14 Suppl 2():S138-42. PubMed ID: 3759248
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Randomized comparison of imipenem/cilastatin and ceftazidime in the empiric therapy of severe abdominal infections. A multicenter study.
    Broze B; De Mees J; Droissart R; Nolens VP; Staudt JP; Verstraeten ME; de Lame PA
    Acta Clin Belg; 1987; 42(6):431-6. PubMed ID: 3324599
    [No Abstract]   [Full Text] [Related]  

  • 76. A randomized study comparing clinical efficacy and safety of thienamycin formamidine (MK0787)/renal dipeptidase inhibitor (MK0791) and cefazolin.
    Ribner BS; Raeder R; Hollstein M; Freimer EH
    J Antimicrob Chemother; 1983 Oct; 12(4):387-91. PubMed ID: 6358177
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI; Fung CP; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Clinical trials of imipenem/cilastatin sodium in the field of obstetrics and gynecology].
    Tateno M
    Jpn J Antibiot; 1986 Jun; 39(6):1595-600. PubMed ID: 3463799
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Imipenem/cilastatin versus aminoglycoside plus amoxicillin plus clindamycin in the treatment of serious postoperative infections.
    Christen D; Buchmann P; Geroulanos S
    Scand J Infect Dis Suppl; 1987; 52():11-4. PubMed ID: 3331039
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
    Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
    Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.